Home › Forums › Main Forum › Experts Corner › velpatasvir or daclatasvir (pangenotypic)

Viewing 4 posts - 1 through 4 (of 4 total)
  • Author
    Posts
  • 21 December 2015 at 10:33 am #6884
    Avatar photoemilio
    • Guardian Angel
    • ★★★★★
    @emilio

    Hi Everyone

    Just wonder what others think. Daclatasvir is no doubt the best pangenotypic NS5A DAA on the market to date, I guess that’s my own opinion based on my own investigation.

    My concern is that soon Gilead will be flogging velpatasvir as a competing NS5A pangenotypic to daclatasvir. Now given that Gilead own sofosbuvir it would stand to reason to suspect that most people on the planet will be offered sofosbuvir and velpatasvir. More so if indeed velpatasvir is a cheaper option to ledipasvir. My issue is that velpatasvir data doesn’t look as good as daclatasvir or ledipasvir regardless of pangenotypic status.

    Okay maybe I’m looking too close at this issue but I’m not convinced velpatasvir is an improvement to HCV treatment options. Em

    PS I understand there is an NZ trial about to commence in Jan using sof/vel for 8 and 12 weeks and is offering this to F4s, crazy.

    21 December 2015 at 10:39 am #6886
    Jimmy6429
    • Topics: 0
    • Replies: 52
    • Total: 52
    • Recovery Champion
    • ★★★★
    @jimmy6429

    Yes the sof/dac looks pretty good by the numbers, sadly compassion and science take a back seat to profit and politics.
    Jim

    3 years cured, Sof/Dac, thanks Doc Freeman, hepc only a distant memory, go for it ppl

    21 December 2015 at 12:02 pm #6893
    dope-on-a-rope.jpgDr James
    • Guardian Angel
    • ★★★★★
    @fixhepc

    http://www.gilead.com/news/press-releases/2015/9/gilead-announces-svr12-rates-from-four-phase-3-studies-evaluating-a-oncedaily-fixeddose-combination-of-sofosbuvir-sof-and-velpatasvir-vel-gs5816-for-the-treatment-of-all-six-hepatitis-c-genotypes

    Treatment emergent serious adverse events occurred in 18 percent of patients and nine patients died.

    If you remove the placebo patients the n was 1593 so the death rate was 1 in 177.

    YMMV

    21 December 2015 at 4:28 pm #6946
    Avatar photosonix
    • Guardian Angel
    • ★★★★★
    @sonix

    The overall cure rate in ASTRAL-1 of 99% looks good but I’d imagine comparable tests of sof/dac and sof/led would be in the same ballpark.

    The majority of serious adverse events and deaths were associated with advanced liver disease.

    Surely some patients with advanced liver disease would die in 12/24 weeks whether treated or not.

    M 61yo HCV+ ~ 30 yrs Gt1a F2 VL 223,000 ALT 54 AST 42 Tx start Sof/Dac 17Dec15.
    SVR4 at 7Apr16 ALT 22 AST 22
    SVR12 at 9Jun16 ALT 23 AST 25
    Melbourne, Australia

  • Author
    Posts
Viewing 4 posts - 1 through 4 (of 4 total)
  • You must be logged in to reply to this topic.